Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4844 - Estrogen-related receptor _ as a potential molecular target for endometrial cancer therapy

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

TETSUYA KOKABU

Citation

Annals of Oncology (2018) 29 (suppl_8): viii1-viii13. 10.1093/annonc/mdy268

Authors

T. KOKABU1, T. Mori1, H. Matsushima1, Y. Tarumi1, K. Yoriki1, H. Kuroboshi1, M. Sawada2, S. Umemura1, J. Kitawaki1

Author affiliations

  • 1 Obstetrics And Gynecology, Kyoto Prefectural University of Medicine, 602-8566 - Kyoto/JP
  • 2 Obstetrics And Gynecology, Kyoto Prefectural University of Medicine, 602 - Kyoto/JP
More

Resources

Abstract 4844

Background

Estrogen-related receptor α (ERRα) is considered to be a potential molecular target against several cancer types. We previously demonstrated that ERRα knockdown regulated tumor progression in uterine endometrial cancer. The purpose of this study was to elucidate the effects of XCT790, a selective inverse agonist of ERRα, on endometrial cancer.

Methods

HEC-1A and KLE cells, endometrial cancer cells with high expression of ERRα, and HEC-1A-derived xenograft mouse model were treated with XCT790. Cell proliferation was evaluated with WST-8 and colony formation assays. The cell cycle was examined with flow cytometry, fluorescent immunocytochemistry. The apoptotic effect was determined with TUNEL assay and caspase-3/7 assay. Proteins and mRNA levels were detected by western blotting and real-time PCR.

Results

XCT790 significantly inhibited ERRα-induced transcriptional activity in a dose-dependent manner (P < 0.01) without reduction of mRNA level of ERRα. XCT790 suppressed colony formation and cell proliferation in a concentration- and time-dependent manner (P < 0.01), without cytotoxicity. Flow cytometry, fluorescence immunocytochemistry, and western blotting indicated that XCT790 induced apoptosis (P < 0.01), and caused cell cycle arrest at the mitotic phase. Western blotting revealed that XCT790 inhibited Akt/mTOR signaling pathway without the alteration of the expression level of PI3K. Additionally, XCT790 significantly suppressed tumor progression in the xenograft mouse model (P < 0.05). XCT790 induced apoptosis and decreased Ki-67 positive cells in tissue sections (P < 0.01).

Conclusions

The findings of the present study suggested that XCT790 could be a novel therapeutic agent in uterine endometrial cancer.

Clinical trial identification

Legal entity responsible for the study

Tetsuya Kokabu.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings